{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:32:33Z","timestamp":1785267153771,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.lansea.2022.100121","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T02:50:57Z","timestamp":1669690257000},"page":"100121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and\u00a0omicron predominance in Thailand: a test-negative, case-control study"],"prefix":"10.1016","volume":"10","author":[{"given":"Kannikar","family":"Intawong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwat","family":"Chariyalertsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittipan","family":"Chalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanachol","family":"Wonghirundecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woravut","family":"Kowatcharakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksara","family":"Thongprachum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narain","family":"Chotirosniramit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worachet","family":"Teacharak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pimpinan khammawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarurin","family":"Waneesorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sopon","family":"Iamsirithaworn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lansea.2022.100121_bib1","author":"Mathieu"},{"key":"10.1016\/j.lansea.2022.100121_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/CEOR.S338225","article-title":"Economic burden of COVID-19: a systematic review","volume":"14","author":"Richards","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.lansea.2022.100121_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bpa.2020.11.009","article-title":"Economic impact of COVID-19 pandemic on healthcare facilities and systems: international perspectives","volume":"35","author":"Kaye","year":"2021","journal-title":"Best Pract Res Clin Anaesthesiol"},{"issue":"6","key":"10.1016\/j.lansea.2022.100121_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11675","article-title":"The combined effect of vaccination and nonpharmaceutical public health interventions-ending the COVID-19 pandemic","volume":"4","author":"Doroshenko","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.lansea.2022.100121_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(21)00143-2","article-title":"Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study","volume":"21","author":"Moore","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lansea.2022.100121_bib6","series-title":"WHO COVID-19 dashboard","year":"2022"},{"key":"10.1016\/j.lansea.2022.100121_bib7","series-title":"WHO COVID-19 vaccines","year":"2022"},{"issue":"1","key":"10.1016\/j.lansea.2022.100121_bib10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1186\/s13063-020-04775-4","volume":"21","author":"Palacios","year":"2020","journal-title":"Trials"},{"issue":"10269","key":"10.1016\/j.lansea.2022.100121_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.lansea.2022.100121_bib12","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.lansea.2022.100121_bib13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14760584.2022.2092472","article-title":"Expert review on global real-world vaccine effectiveness against SARS-CoV-2","volume":"21","author":"Chuenkitmongkol","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"10.1016\/j.lansea.2022.100121_bib14","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.lansea.2022.100121_bib15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"issue":"10303","key":"10.1016\/j.lansea.2022.100121_bib16","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of\u00a0heterologous versus homologous prime-boost schedules with an\u00a0adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"issue":"10295","key":"10.1016\/j.lansea.2022.100121_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.lansea.2022.100121_bib18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJMc2200415","article-title":"Effectiveness of homologous or heterologous Covid-19 boosters in veterans","volume":"386","author":"Mayr","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.lansea.2022.100121_bib19","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMc2203165","article-title":"Effectiveness of homologous and heterologous Covid-19 boosters against omicron","volume":"386","author":"Accorsi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lansea.2022.100121_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbrc.2021.01.093","article-title":"Application technology to fight the COVID-19 pandemic: lessons learned in Thailand","volume":"538","author":"Intawong","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.lansea.2022.100121_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101542","article-title":"Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study","volume":"51","author":"Ascaso-Del-Rio","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lansea.2022.100121_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101529","article-title":"Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S\/BNT162b2 vaccination: secondary analysis of the randomised CombiVacS study","volume":"50","author":"Garc\u00eda-P\u00e9rez","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.lansea.2022.100121_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/22221751.2022.2037398","article-title":"Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study","volume":"11","author":"Sritipsukho","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"10.1016\/j.lansea.2022.100121_bib25","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.4.2200077","article-title":"Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022","volume":"27","author":"Veneti","year":"2022","journal-title":"Euro Surveill"},{"issue":"10332","key":"10.1016\/j.lansea.2022.100121_bib26","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lansea.2022.100121_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277236822200138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277236822200138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:29:54Z","timestamp":1762644594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277236822200138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":24,"alternative-id":["S277236822200138X"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2022.100121","relation":{},"ISSN":["2772-3682"],"issn-type":[{"value":"2772-3682","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and\u00a0omicron predominance in Thailand: a test-negative, case-control study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2022.100121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100121"}}